NASDAQ · SURGICAL & MEDICAL INSTRUMENTS & APPARATUS · SMALL CAP
Glucotrack, Inc. GCTK
19 fiscal years on record · USD · FY2025 reported
SEC FILINGS ONLY
EPS · FY25
$-31.22
Dividend / sh · FY25
—
Payout · FY25
—
ROE · FY25
—
Net margin · FY25
—
Dividend coverage
—
Advertisement
AdSense · Leaderboard 728×90320×100
Result
—
Revenue, FY2025 · full 19-year series below
Revenue
Net income
Per share
USD -31.22
Diluted EPS, FY2025
EPS
The company pays no cash dividend.
Profitability
—
Return on equity, FY2025
ROE
Operating margin—
Net margin—
Return on assets-281.6%
Returned to shareholders
—
returned in FY2025 · dividends + net buybacks
Dividends paid—
Net buybacks—
Share of profit—
Consecutive raises—
Growth
+28.3% a year
revenue, compounded over five years
CAGR
3 yrs
5 yrs
10 yrs
15 yrs
Revenue
−30.2%
+28.3%
Compound annual rates per period — left blank where the series crosses a loss.
Share base
0.00B
Shares outstanding, FY2025
Change, 5 years+24.9%
Change, 10 years—
The share count grew 25% in five years — the same company, cut into more, smaller slices.
Advertisement
AdSense · Leaderboard 728×90300×250
Balance sheet
USD 7.8M
total assets, end of FY2025
Total assetsUSD 7.8M
EquityUSD 2.8M
CashUSD 7.4M
Current ratio1.61×
Equity funds 36% of total assets.
History
19 fiscal years
Every figure from documents filed with the SEC · USD
Metric
2025
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
2011
2010
2009
2008
2007
Revenue $B
·
·
·
·
·
·
0.0
0.0
0.0
0.0
0.0
0.0
·
·
·
·
·
·
·
Operating income $B
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
0.0
−0.0
0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
·
·
EBITDA $B
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
0.0
−0.0
0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
·
·
Income tax $B
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
Net income $B
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
0.0
−0.0
0.0
−0.0
−0.0
0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
EPS, diluted $
−31.22
−4106.00
−34.18
−0.29
0.26
0.19
0.02
−4.74
−1.87
−1.08
−1.15
0.37
−1.95
−0.52
−0.46
−0.70
0.30
·
·
Dividend / sh $
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
Payout %
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
ROE %
·
·
−320.6
−138.9
−57.5
−71.2
·
·
·
·
·
·
·
−1192.0
−301.9
·
·
−516.6
−293.8
Shares out B
0.00
0.00
0.00
0.02
0.02
0.02
0.16
0.14
0.01
0.01
0.01
0.01
0.01
0.01
0.01
0.00
·
·
·
Slide the table for earlier years · "·" marks figures not disclosed in the filing for that year.
How we verifyAUDITED
48 of 48
checks passed before publication
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidity
Every figure was compared against the original statement: 0 failures and 0 presentation gaps.
What we don’t show
We’d rather say what’s missing than fill the gap with an estimate.
P/E rationeeds a market quote — not yet licensed
Market capitalizationneeds a market quote — not yet licensed
Dividend yieldneeds a market quote — not yet licensed
Price-to-bookneeds a market quote — not yet licensed